Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.

Acta biochimica et biophysica Sinica - 1 Apr 2018

Wu Zhenhua, Huang Mingzhu, Gong Yiwei, Lin Chen, Guo Weijian

Abstract excerpt

Mutations in the oncogene BRAF(V600E) are found in ~10% of colorectal cancers (CRCs) and are associated with poor prognosis. However, BRAF(V600E) has a limited response to the small-molecule drug, vemurafenib, a BRAF inhibitor, and BRAF inhibition is thought to cause a feedback activation of EGFR signaling that supports continued proliferation. In this study, we explored the effect of combined use of dabrafenib,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Imidazoles

Share to Neoplasm Transplantation

Share to Neoplastic Stem Cells

Share to Oximes

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 29534162
DOI: 10.1093/abbs/gmy018

Genes

BRAF
EGFR
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.PMID 29534162Read ↗

Morusin inhibits the growth of human colorectal cancer HCT116‑derived sphere‑forming cells via the inactivation of Akt pathwaySemantic proximity Read ↗

AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.Semantic proximity Read ↗

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.Semantic proximity Read ↗

Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.Semantic proximity Read ↗

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.Semantic proximity Read ↗

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.Semantic proximity Read ↗

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.Semantic proximity Read ↗

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factorsSemantic proximity Read ↗

Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancerSemantic proximity Read ↗

KRAS Mutation Reduces Thymoquinone Anticancer Effects on Viability of Cells and Apoptosis.Semantic proximity Read ↗

Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.Semantic proximity Read ↗

Improvement of 5-Fluorouracil Chemosensitivty In Colorectal Cancer Cells by siRNA-Mediated Silencing of STAT6 OncogeneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.